U.S. Over the Counter (OTC) Drugs Market Size, Share, and Trends 2024 to 2033

U.S. Over the Counter (OTC) Drugs Market (By Product Type: Vitamin and Dietary Supplements, Cough and Cold Products, Analgesics, Gastrointestinal Products, Sleep Aids, Otic Products, Wart Removers, Mouth Care Products, Ophthalmic Products, Botanicals, Antacids, Smoking Cessation Products, Feminine Care, Others; By Dosage Form; By Route of Administration; By Distribution Channel) - Regional Outlook and Forecast 2024 to 2033

  • Last Updated : February 2024
  • Report Code : 3753
  • Category : Healthcare

The U.S. over the counter (OTC) drugs market size was estimated at USD 23.03 billion in 2023 and is projected to hit around USD 41.72 billion by 2033, growing at a CAGR of 6.42% from 2024 to 2033.

U.S. Over the Counter (OTC) Drugs Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways

  • By product type, the cough & cold products segment held the largest share of the market in 2023, the segment is observed to witness a notable growth during the forecast period.
  • By dosage form, the tablets segment dominated the market with the largest share in 2023.
  • By route of administration, the oral segment held the largest share of the market and is expected to sustain the position throughout the forecast period.
  • By distribution channel, the drug stores & retail pharmacies segment dominated the U.S. over the counter (OTC) drugs market in 2023.

U.S. Over the Counter (OTC) Drugs Market Overview

Over the counter drugs refer to medications that are available for purchase without a prescription from a healthcare professional. These drugs are also known as non-prescription drugs and are typically found on the shelves of pharmacies, supermarkets, and convenience stores. Unlike prescription drugs, which require a healthcare provider's authorization, OTC drugs can be bought directly by consumers for self-medication.

OTC drugs are generally considered safe when used as directed and for the intended purpose. They are commonly used to treat minor health conditions such as headaches, cold and flu symptoms, allergies, and mild pain. Common examples of OTC drugs include pain relievers like acetaminophen and ibuprofen, cough and cold medications, antacids, allergy medications, and topical creams for skin conditions.

Growth Factors

  • The growing number of people using over the counter drugs to treat minor illnesses is one of the main drivers of the U.S. over the counter (OTC) drugs market’s expansion.
  • Furthermore, major businesses are diversifying their product lines to reach a larger audience and establish a stronger presence across more regions. The market is being favorably impacted by this as well as the growing number of regulatory bodies' authorization allowing patients to transition from prescription to over the counter drugs.
  • In addition, OTC medicines such as antacids, proton pump inhibitors (PPIs), and histamine-2 (H2) blockers are used to treat and prevent acid reflux disease (GERD). In addition, people are becoming more conscious of the value of self-care as a result of the coronavirus illness (COVID-19) outbreak. Consequently, this is driving up sales of dietary supplements and supporting the expansion of the U.S. over the counter (OTC) drugs market.

U.S. Over the Counter (OTC) Drugs Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 6.42%
U.S. Market Size in 2023 USD 23.03 Billion
U.S. Market Size by 2033 USD 41.72 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product Type, By Dosage Form, By Route of Administration, and By Distribution Channel

U.S. Over the Counter (OTC) Drugs Market Dynamics

Driver: Increasing prevalence of various disease

Acute and chronic illnesses such as respiratory, neurological, orthopedic, and cardiovascular conditions are becoming more prevalent in the US. Every year in the US, heart failure is diagnosed in over 550,000 persons. The Centers for Disease Control and Prevention (CDC) estimate that every year, over 790,000 Americans suffer from a heart attack; of them, about 580,000 experience their first heart attack and 210,000 experience their second. Diabetes, hypertension, tobacco use, obesity, and other risk factors are making chronic cardiac, neurological, and orthopedic illnesses more common.

As the prevalence of chronic illnesses has increased, so has the usage of medications as people look for easy and efficient ways to manage their conditions. For instance, aspirin is frequently used in people with a history of heart disease or who are at high risk of developing heart disease to prevent heart attacks, strokes, and other cardiovascular disorders. In the same way, acetaminophen and ibuprofen are frequently used to lessen pain and inflammation brought on by ailments including headaches, chronic pain in the back, and arthritis. Thus, the increasing prevalence of various diseases drives the U.S. over the counter (OTC) drugs market.

Restraint: Safety concerns and regulatory challenge

OTC medications are typically regarded as safe when used as prescribed, however, abuse or overuse of them may raise safety issues. Making sure that products are safe for consumers is a continuous problem since certain components may have negative effects or interact with other treatments.

Furthermore, the market for over the counter drugs is governed by rules, and modifications to these regulations may affect the accessibility and promotion of certain OTC drugs. Regulatory obstacles may impact the status of already-approved OTC medications or delay the launch of new ones. Therefore, safety concerns and regulatory challenges might be a major impeding factor to the U.S. over the counter (OTC) drugs market's growth.

Opportunity: Growing approvals

The increasing approvals in the industry are expected to offer an attractive opportunity for market growth during the forecast period. For instance, in August 2023, the U.S. Food and Drug Administration (FDA) authorized ZURZUVAETM (zuranolone) 50 mg for people with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and only oral, once-daily, 14-day medication that can significantly reduce depression symptoms.

Furthermore, a Complete Response Letter (CRL) was released by the FDA about the New Drug Application (NDA) for zuranolone, which is intended to treat the major depressive disorder (MDD) in adults. The CRL declared that further research or studies would be required since the application did not offer sufficient proof of efficacy to justify the approval of zuranolone for the treatment of MDD. Sage and Biogen are analyzing the comments and planning the next phase of action.

Product Type Insights

The cough & cold products segment held the largest share of the U.S. over the counter (OTC) drugs market in 2023. A wide variety of viruses can cause the common cold. The illness is usually harmless, and symptoms go away in two weeks on average. The growth in over the counter (OTC) medicine use in this category can be attributed to the rise in the number of persons who are afflicted with cough, cold, and flu. As a last option, consumers rely on over-the-counter medications for cough, cold, or flu symptoms.

  • For instance, the CDC reports that the common cold results in 22 million lost school days annually in the US. In addition, about 1 billion Americans have colds annually.

Dosage Form Insights

The tablets segment held the largest share of the U.S. over the counter (OTC) drugs market in 2023. Over the counter tablets are available in a wide range of therapeutic areas, such as digestive health, allergy relief, cold and flu treatment, pain management, and more. To treat various ailments, tablets may contain a single active ingredient or a mixture of active compounds. Additionally, customers frequently choose tablets for self-medication since they are a practical and simple dosing type. They may be taken without water in some situations due to their discreet and portable design, which makes them popular.

Route of Administration Insights

The oral segment held the dominating share of the market in 2023. The segment is observed to sustain the position in the upcoming period. Oral drugs provide a convenient method of medication delivery, allowing patients to take their medication at home or on the go without the need for medical supervision. This convenience promotes better adherence to treatment plans.

In addition, compared to some other routes of administration (such as injections or intravenous infusions), taking medications orally is generally less invasive and more comfortable for patients. Thus, these advantages drive the segment expansion.

Distribution Channel Insights

The drug stores & retail pharmacies segment held the largest share of the U.S. over the counter (OTC) drugs market in 2023. Drug stores and retail pharmacies provide a diverse range of OTC drugs that cater to different health needs. This includes pain relievers, cough and cold medications, allergy remedies, digestive aids, vitamins, and more. Thus, the availability of these products allows consumers to address common health concerns without visiting a healthcare provider for a prescription.

Recent Developments

  • In July 2023, a leading manufacturer of consumer self-care products Perrigo Company plc announced that Opill®, a daily oral contraceptive that solely contains progestin, has been authorized by the FDA for use by people of all ages as an over-the-counter (OTC) medication. The first birth control pill to be sold over-the-counter in the US was called Opill.
  • In June 2023, Foster & Thrive, a carefully chosen private brand of over-the-counter (OTC) health and wellness products, was recently introduced by McKesson Corporation MCK. The launch will include OTC items bearing the Health Mart and Sunmark brands, to unify the company's private brand portfolio.

Key Market Players

  • Bayer AG
  • Takeda Pharmaceutical Company Ltd.
  • Pfizer
  • Johnson & Johnson Services Inc.
  • Sanofi S.A.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline PLC
  • Mylan
  • UPM Pharmaceuticals

Segments Covered in the Report

By Product Type

  • Vitamin and Dietary Supplements
  • Cough & Cold Products
  • Analgesics
  • Gastrointestinal Products
  • Sleep Aids
  • Otic Products
  • Wart Removers
  • Mouth Care Products
  • Ophthalmic Products
  • Botanicals
  • Antacids
  • Smoking Cessation Products
  • Feminine Care
  • Others

By Dosage Form

  • Tablets
  • Hard Capsules
  • Powders
  • Ointments
  • Soft Capsules
  • Liquids
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The U.S. over the counter (OTC) drugs market size is expected to increase USD 41.72 billion by 2033 from USD 23.03 billion in 2023.

The U.S. over the counter (OTC) drugs market will register growth rate of 6.42% between 2024 and 2033.

The major players operating in the U.S. over the counter (OTC) drugs market are Bayer AG, Takeda Pharmaceutical Company Ltd., Pfizer, Johnson & Johnson Services Inc., Sanofi S.A., Novartis AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Mylan, UPM Pharmaceuticals, and Others.

The driving factors of the U.S. over the counter (OTC) drugs market are the growing number of regulatory bodies and increasing prevalence of various disease.

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client